Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial ...
For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...
Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), ...
PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the ...
The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 ...
Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.
Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial.
News Medical on MSN5h
PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancerAlliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...
Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating ...
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...
Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback